{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:04:54Z","timestamp":1792782294101,"version":"4.5.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":2144,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III, Ministerio de Ciencia, Innovaci\u00f3n y Universidades, Spain","award":["PIE14\/00066"],"award-info":[{"award-number":["PIE14\/00066"]}],"id":[{"id":"https:\/\/ror.org\/05r0vyz12","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100008530","name":"EU\u2013European Regional Development Fund","doi-asserted-by":"publisher","award":["PIE14\/00066"],"award-info":[{"award-number":["PIE14\/00066"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish Cardiovascular Network","award":["PIE14\/00066"],"award-info":[{"award-number":["PIE14\/00066"]}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PIE14\/00066"],"award-info":[{"award-number":["PIE14\/00066"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Current guidelines recommend sacubitril\/valsartan for patients with heart failure and reduced left ventricular ejection fraction (LVEF), but there is lack of evidence of its efficacy and safety in cancer therapy-related cardiac dysfunction (CTRCD). Our aim was to analyse the potential benefit of sacubitril\/valsartan in patients with CTRCD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We performed a retrospective multicentre registry (HF-COH) in six Spanish hospitals with cardio-oncology clinics including all patients treated with sacubitril\/valsartan. Demographic and clinical characteristics and laboratory and echocardiographic data were collected. Median follow-up was 4.6 [1; 11] months. Sixty-seven patients were included (median age was 63 \u00b1 14 years; 64% were female, 87% had at least one cardiovascular risk factor). Median time from anti-cancer therapy to CTRD was 41 [10; 141] months. Breast cancer (45%) and lymphoma (39%) were the most frequent neoplasm, 31% had metastatic disease, and all patients were treated with combination antitumor therapy (70% with anthracyclines). Thirty-nine per cent of patients had received thoracic radiotherapy. Baseline median LVEF was 33 [27; 37], and 21% had atrial fibrillation. Eighty-five per cent were on beta-blocker therapy and 76% on mineralocorticoid receptor antagonists; 90% of the patients were symptomatic NYHA functional class \u2265II. Maximal sacubitril\/valsartan titration dose was achieved in 8% of patients (50 mg b.i.d.: 60%; 100 mg b.i.d.: 32%). Sacubitril\/valsartan was discontinued in four patients (6%). Baseline N-terminal pro-B-type natriuretic peptide levels (1552 pg\/mL [692; 3624] vs. 776 [339; 1458]), functional class (2.2 \u00b1 0.6 vs. 1.6 \u00b1 0.6), and LVEF (33% [27; 37] vs. 42 [35; 50]) improved at the end of follow-up (all P values \u22640.01). No significant statistical differences were found in creatinine (0.9 mg\/dL [0.7; 1.1] vs. 0.9 [0.7; 1.1]; P = 0.055) or potassium serum levels (4.5 mg\/dL [4.1; 4.8] vs. 4.5 [4.2; 4.8]; P = 0.5). Clinical, echocardiographic, and biochemical improvements were found regardless of the achieved sacubitril\u2013valsartan dose (low or medium\/high doses).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our experience suggests that sacubitril\/valsartan is well tolerated and improves echocardiographic functional and structural parameters, N-terminal pro-B-type natriuretic peptide levels, and symptomatic status in patients with CTRCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.12627","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T07:32:50Z","timestamp":1580887970000},"page":"763-767","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":71,"title":["Effectiveness of Sacubitril\u2013Valsartan in Cancer Patients with Heart Failure"],"prefix":"10.1093","volume":"7","author":[{"given":"Ana","family":"Mart\u00edn-Garcia","sequence":"first","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Salamanca\u2014IBSAL, University of Salamanca , Paseo de San Vicente 58-187, 37007, Salamanca ,","place":["Spain"]},{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital La Paz\u2014IdiPAZ , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Mitroi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Puerta de Hierro\u2014IDIPHISA, Majadahonda , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinela","family":"Chaparro-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Virgen de la Macarena\u2014IBiS , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Moliner","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitari Germans Trias I Pujol\u2014IGTP, Badalona , Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin C.","family":"Martin-Garcia","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Salamanca\u2014IBSAL, University of Salamanca , Paseo de San Vicente 58-187, 37007, Salamanca ,","place":["Spain"]},{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Martinez-Monzonis","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Cl\u00ednico Universitario de Santiago de Compostela\u2014IDIS , Santiago de Compostela, A Coru\u00f1a ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Castro","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital Virgen de la Macarena\u2014IBiS , Seville ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose L.","family":"Lopez-Sendon","sequence":"additional","affiliation":[{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]},{"name":"Department of Cardiology, Hospital La Paz\u2014IdiPAZ , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hospital Universitario de Salamanca\u2014IBSAL, University of Salamanca , Paseo de San Vicente 58-187, 37007, Salamanca ,","place":["Spain"]},{"name":"CIBERCV, Instituto de Salud Carlos III , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"2026012115051859900_ehf212627-bib-0001","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1056\/NEJM200004133421502","article-title":"Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy","volume":"342","author":"Felker","year":"2000","journal-title":"N Engl J Med"},{"key":"2026012115051859900_ehf212627-bib-0002","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1016\/j.healun.2004.12.108","article-title":"Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure","volume":"24","author":"Tallaj","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"2026012115051859900_ehf212627-bib-0003","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/ejhf.1049","article-title":"Comparison of long-term outcome in anthracycline-related versus idiopathic dilated cardiomyopathy: a single centre experience","volume":"20","author":"Fornaro","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012115051859900_ehf212627-bib-0004","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012115051859900_ehf212627-bib-0005","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012115051859900_ehf212627-bib-0006","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Committees, Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012115051859900_ehf212627-bib-0007","first-page":"474","article-title":"Cardio-onco-hematology in clinical practice. Position paper and recommendations","volume":"70","author":"Lopez-Fernandez","journal-title":"Revista espanola de cardiologia Rev Esp Cardiol (Engl Ed)"},{"key":"2026012115051859900_ehf212627-bib-0008","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.mayocp.2015.09.009","article-title":"Prevalence of preexisting cardiovascular disease in patients with different types of cancer: the unmet need for onco-cardiology","volume":"91","author":"Al-Kindi","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2026012115051859900_ehf212627-bib-0009","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1093\/eurheartj\/ehy453","article-title":"Cardio-oncology services: rationale, organization, and implementation","volume":"40","author":"Lancellotti","year":"2019","journal-title":"Eur Heart J"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fehf2.12627","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ehf2.12627","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ehf2.12627","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/2\/763\/65807945\/eschf_7_2_763.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/7\/2\/763\/65807945\/eschf_7_2_763.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T20:06:19Z","timestamp":1769025979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/7\/2\/763\/8373126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2,5]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.12627","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4]]},"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"2019-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-01-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}